Peptide nucleic acid as therapeutic agent


 PNA are synthetic analog of DNA with a repeating N-(2-aminoethyl)-glycine peptide backbone connected to purine and pyrimidine nucleobases via a linker. The unique properties of PNA, including resistance to enzymatic digestion, higher bio stability combined with great hybridization affinity toward DNA and RNA, it has attracted great attention toward PNA- based technology as a promising approach for gene alteration. However, an important challenge in utilizing PNA is poor intracellular uptake. Some strategies have been developed to enhance the delivery of PNA in order to reach cognate site.



 



 


    Related Conference of Peptide nucleic acid as therapeutic agent

    September 27-28, 2021

    25th European Biotechnology Congress

    Dublin, Ireland
    September 29-29, 2021

    27th Asia Pacific Biotechnology Congress

    London, UK
    November 18-19, 2021

    25th World Congress on Pharmaceutical Biotechnology

    Barcelona, Spain
    November 22-23, 2021

    23rd Global Biotechnology Congress

    Rome, Italy
    December 01-02, 2021

    18th International Conference on Metabolomics and Proteomics

    Frankfurt, Germany
    December 08-09, 2021

    World Congress on Biosensors and Bioelectronics

    London, UK
    December 08-08, 2021

    2nd International Conference on Nucleic Acids

    London, UK
    December 27-27, 2021

    12th Tissue Repair and Regeneration Congress

    Dubai, UAE
    December 30-30, 2021

    Glycobiology Biochem Conference 2021

    London, UK
    February 25-26, 2022

    International Conference on Biotechnology

    Singapore City,Singapore
    May 02-03, 2022

    12th World Glycobiology Congress

    Zurich, Switzerland
    August 22-23, 2022

    15th International Conference on Proteomics, Genomics & Bioinformatics

    Singapore City, Singapore

    Peptide nucleic acid as therapeutic agent Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in